The use of a CD20-specific monoclonal antibody to selectively remove B2 cells, but not B1a cells, from ApoE-/- and Ldlr-/- mice reduced atherogenesis and progression of atherosclerosis (73, 74). This evidence concerns the gene LDLR and atherosclerosis.